Ah Marzo!!!!So much vitriol, for someone with a different idea...

Ah Marzo!!!!
So much vitriol, for someone with a different idea to you. For someone so new to investing such as yourself, I would have thought you would be more interested in learning and asking questions, rather than attacking other forum posters.

Why don’t we look at some facts:
Technology development is a high risk business with most ideas taking at least 5-8 years from patent to making a profit. That’s if they get there in the first place as most patents do not end up as profitable ideas. From experience it’s about a strike rate of 1 in 10.

Datadot has side stepped the business of technology development and buys its technologies from organisations such as CSIRO, who undertake the riskier part of development, in return for a stake in the business.

Datadot currently has four products (I don’t count DatabaseDNA as a product)
DataDotDNA which is a good product with the application technology patented in 2005. It slowly appears to be gaining customers. I am one of them and was very pleased with the ease of purchasing and application. With time I would expect this product to take the company to a profitable stage and form the basis of a steady income. The announcements in the past year would suggest this to be viable, but I await the annual report to see the current state of sales. The GFC has caused a number of problems in DDT’s markets and thus has made growth slower than I would expect. I do not expect this product to make DDT a 10 bagger.

DataThreadDNA is a minor product at the moment and I don’t expect much growth in this area as I think it will always be a niche product.

Intelliseed is a high quality product with a potentially large market associated with counterfeiting of seed products. This is where I expect growth as seed companies endeavour to protect their IP associated with seeds with improved productivity and disease resistance. I don’t however expect to see a large market tomorrow or even next year as it will be a gradual uptake. However, they might have a slight problem in the USA as Monsanto have a trademark on “Intelliseed”.

DataTraceDNA
This is their final product patented in 2005 and the one where all the press has been related to because of disclosure by a scientist made redundant from CSIRO. He claims that cheap phosphorescence products were used in the manufacture, which could be counterfeited. Honestly I don’t know what to believe in this situation. CSIRO has released a press release on this issue as has DataDot . I would have thought that if CSIRO were at fault then they would be liable. As far as I can see the technology is sound, but the application in the case with Novartis could have been compromised. Again this product would just be moving into the area of profitability. The issue with Novartis may have irreparably damaged this product, but I will wait for the annual report before I make a judgement.

I have less than 10% of my portfolio in stocks such as DDT. I am happy if 1 in 4 is successful which gives me a better return than I can get elsewhere. So far SRX, CSL, RMD and COH have done this for me. I am hopeful for NAN, UBI, and SOM. I still have an open mind on DDT, but with my success rate with the others I am happy to take the risk. If I am right someone may like to take my large holding of my hands. If I am wrong I will have lost a small proportion of my portfolio. I am happy if you wish to tell me I am wrong on the above, but please use logical rather than emotive language.